Evaluation of bivalirudin based anticoagulation for extracorporeal membrane oxygenation including patients with COVID-19
The Journal of ExtraCorporeal Technology · 2025
DOI: 10.1051/ject/2025045 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of ExtraCorporeal Technology, 2025. Verfasst von Miranda Raguindin und 5 weiteren Autor:innen. Beteiligte Einrichtung: Carilion Roanoke Memorial Hospital, Roanoke, VA 24014, USA - Hartford Hospital, Hartford, CT 06106, USA. Hauptthemen laut MEDLINE: Extracorporeal Membrane Oxygenation, Hirudins, Peptide Fragments, COVID-19. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Background
Although unfractionated heparin (UFH) has traditionally been used for anticoagulation during extracorporeal membrane oxygenation (ECMO), bivalirudin may be preferred due to fewer complications. A prior medication use evaluation of ECMO patients who received bivalirudin resulted in dosing updates to our pharmacist-directed bivalirudin protocol. The intent of this study was to evaluate the efficacy and safety of bivalirudin for anticoagulation during ECMO support post protocol initiation.
Methods
This was a retrospective, single-center, quasi-experimental, pre-post study. Adult patients requiring ECMO support for at least 24 hours and who received bivalirudin between January 1, 2015 to July 31, 2018 (pre-group) and May 1, 2019 to June 30, 2021 (post-group) were included.
Results
There were 38 patients in the pre- and 35 patients in the post-group. The primary outcome, median time to two consecutive activated partial thromboplastin times (aPTTs) within therapeutic range for the initial goal range, was 8.9 hours in the pre- and 14.2 hours in the post-group (p=0.517). In a subgroup analysis of the post-group, the primary outcome was higher in patients with COVID-19 (26.5 vs. 8.6 hours, p=0.018). The median number of dose adjustments to achieve goal aPTT was higher in COVID-19 patients (4 vs. 2, p=0.017).
Conclusion
These results suggest that a standardized pharmacist-directed protocol for bivalirudin in ECMO achieves timely therapeutic anticoagulation levels. Patients with COVID-19 trended toward longer times to two consecutive therapeutic aPTTs. Further studies are needed evaluating dosing strategies in patients with and without COVID-19.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Carilion Roanoke Memorial Hospital, Roanoke, VA 24014, USA - Hartford Hospital, Hartford, CT 06106, USA.
- Carilion Roanoke Memorial Hospital, Roanoke, VA 24014, USA - North Florida Regional Medical Center, Gainesville, FL 32605, USA.
- Carilion Roanoke Memorial Hospital, Roanoke, VA 24014, USA - Sentara Virginia Beach General Hospital, Virginia Beach, VA 23454, USA.
- Carilion Roanoke Memorial Hospital, Roanoke, VA 24014, USA - Duke Raleigh Hospital, Raleigh, NC 27609, USA.
- Carilion Roanoke Memorial Hospital, Roanoke, VA 24014, USA.
ORCID-Profile: Miranda Raguindin, Hasan Kazmi, Ashley Milkovits
Zitieren
APA
Raguindin, M., Bardsley, C., Bast, C., Sugrue, D., Kazmi, H., & Milkovits, A. (2025). Evaluation of bivalirudin based anticoagulation for extracorporeal membrane oxygenation including patients with COVID-19. The Journal of ExtraCorporeal Technology. https://doi.org/10.1051/ject/2025045
Vancouver
Raguindin M, Bardsley C, Bast C, Sugrue D, Kazmi H, Milkovits A. Evaluation of bivalirudin based anticoagulation for extracorporeal membrane oxygenation including patients with COVID-19. The Journal of ExtraCorporeal Technology. 2025. doi:10.1051/ject/2025045
BibTeX
@article{Raguindin2025,
author = {Raguindin, Miranda and Bardsley, Casey and Bast, Chelsea and Sugrue, David and Kazmi, Hasan and Milkovits, Ashley},
title = {Evaluation of bivalirudin based anticoagulation for extracorporeal membrane oxygenation including patients with COVID-19},
journal = {The Journal of ExtraCorporeal Technology},
year = {2025},
doi = {10.1051/ject/2025045}
}
EUVIMED